全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

鼠神经生长因子联合甲钴胺短期治疗糖尿病痛性神经病变的疗效观察

, PP. 1593-1595

Keywords: 鼠神经生长因子,甲钴胺,痛性糖尿病神经病变,疗效

Full-Text   Cite this paper   Add to My Lib

Abstract:

目的探讨鼠神经生长因子联合甲钴胺治疗痛性糖尿病神经病变的疗效。方法选择痛性糖尿病神经病变患者83例,随机分为单用甲钴胺组(A组)42例,甲钴胺+鼠神经生长因子组(B组)41例,均连续治疗14天,治疗前后采用视觉模拟评分(VisualAnalogueScale,VAS)和匹茨堡睡眠质量指数量表(PittsburghSleepQualityIndex,PSQI)评估,及正中神经,胫神经,腓总神经的运动神经传导速度(motornerveconductionvelocity,MCV)和感觉神经传导速度(sensorynerveconductionvelocity,SCV)检查。结果A、B两组在治疗后VAS评分(A组7.36±1.56vs7.39±1.63,B组5.12±1.24vs3.95±1.01)和PSQI评分(A组15.33±2.51vs15.84±2.36,B组11.28±2.09vs10.07±2.21)均有下降,而B组较A组降低更明显,有统计学意义(P<0.05);治疗后B组腓总神经的MCV较治疗前有提高(33.86±3.21vs36.03±3.25),有统计学意义(P<0.05),B组胫神经的SCV较治疗前(32.04±3.28vs36.89±3.45)和A组(33.03±3.5vs36.89±3.45)都有提高,有统计学意义(P<0.05);A组总有效率48.8%,B组总有效率75.6%,有统计学意义(P<0.05)。结论鼠神经生长因子联合甲钴胺治疗痛性糖尿病神经病变效果优于单用甲钴胺。

References

[1]  Veves A, Backonja M, Malik R A. Painful diabetic neuropathy:? epidemiology, natural history, early diagnosis, and treatment options[J]. Pain Med, 2008, 9(6): 660-674. [2]Sadosky A, Schaefer C, Mann R, et al. Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US:? results from a retrospective chart review and cross-sectional survey[J]. Diabetes Metab Syndr Obes, 2013, 6:? 79-92. [3]Rosenberg C J, Watson J C. Treatment of painful diabetic peripheral neuropathy[J]. Prosthet Orthot Int, 2015, 39(1):? 17-28. [4]Vadivelu N, Kai A, Maslin B, et al. Tapentadol extended release in the management of peripheral diabetic neuropathic pain[J]. Ther Clin Risk Manag, 2015, 11: 95-105. [5]Zhuo M, Wu G, Wu L J. Neuronal and microglial mechanisms of neuropathic pain[J]. Mol Brain, 2011, 4:? 31. [6]Vincent A M, Callaghan B C, Smith A L, et al. Diabetic neuropathy:? cellular mechanisms as therapeutic targets[J]. Nat Rev Neurol, 2011, 7(10): 573-583. [7]张岱, 王佑民. 糖尿病痛性神经病变[J]. 安徽医药, 2011, 15(12): 1595-1598. [8]Azhary H, Farooq M U, Bhanushali M, et al. Peripheral neuropathy:? differential diagnosis and management[J]. Am Fam Physician, 2010, 81(7): 887-892. [9]Fonseca V A, Lavery L A, Thethi T K, et al. Metanx in type 2 diabetes with peripheral neuropathy:? a randomized trial[J]. Am J Med, 2013, 126(2): 141-149. [10]Xu Q, Pan J, Yu J, et al. Meta-analysis of methylcobalamin alone and in combination with lipoic acid in patients with diabetic peripheral neuropathy[J]. Diabetes Res Clin Pract, 2013, 101(2): 99-105. [11]Hernandez-Ojeda J, Cardona-Munoz E G, Roman-Pintos L M, et al. The effect of ubiquinone in diabetic polyneuropathy:? a randomized double-blind placebo-controlled study[J]. J Diabetes Complications, 2012, 26(4): 352-358. [12]Wang H, Romano G, Frustaci M E, et al. Fulranumab for treatment of diabetic peripheral neuropathic pain:? A randomized controlled trial[J]. Neurology, 2014, 83(7):? 628- 637. [13]Xu G, Lv Z W, Feng Y, et al. A single-center randomized controlled trial of local methylcobalamin injection for subacute herpetic neuralgia[J]. Pain Med, 2013, 14(6):? 884-894. [14]杨怡, 宋晓华, 刘金艳;等. α-硫辛酸联合甲钴胺注射液治疗糖尿病周围神经病变临床价值分析[J]. 中国医药导报, 2012, 9(8) :? 86-87. [15]Rocco M L, Balzamino B O, Petrocchi-Passeri P, et al. Effect of Purified Murine NGF on Isolated Photoreceptors of a Rodent Developing Retinitis Pigmentosa[J]. PLoS One, 2015, 10(4):? e0124810. ?
[2]  任欣,曹洪义,陈应辉.甲钴胺和胞磷胆碱片联用对糖尿病周围神经病变的疗效观察[J].第三军医大学学报,2012,34(18):1893.  Ren Xin,Cao Hongyi,Chen Yinghui.Therapeutic effect of mecobalamine and citicoline on diabetic peripheral neuropathy: report of 120 cases[J].J Third Mil Med Univ,2012,34(15):1893.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133